Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians

Background  Epidermal growth factor receptor (EGFR) inhibitors are part of the therapeutic arsenal available for advanced cancer. However, they are frequently associated with cutaneous side‐effects, which can hamper compliance, lead to treatment refusal and impair quality of life.

[1]  A. Hauschild,et al.  Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Deplanque,et al.  CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. , 2010 .

[3]  M. Lacouture,et al.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Hofheinz,et al.  Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists , 2010, Oncology Research and Treatment.

[5]  M. Lacouture,et al.  Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. , 2010, Journal of the National Cancer Institute.

[6]  Lynne Wagner,et al.  A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group , 2010, Supportive Care in Cancer.

[7]  J. Soria,et al.  Cutaneous side‐effects in patients on long‐term treatment with epidermal growth factor receptor inhibitors , 2009, The British journal of dermatology.

[8]  E. Van Cutsem,et al.  Skin toxicities of targeted therapies. , 2009, European journal of cancer.

[9]  O. Bouché,et al.  [Targeted biotherapies in digestive oncology: management of adverse effects]. , 2009, Gastroenterologie clinique et biologique.

[10]  M. Lacouture.  The growing importance of skin toxicity in EGFR inhibitor therapy. , 2009, Oncology.

[11]  M. Lacouture,et al.  Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations , 2009, Current oncology.

[12]  B. Thiers.  Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-induced Skin Rashes: Results of a Placebo-controlled Trial From the North Central Cancer Treatment Group (N03CB) , 2009 .

[13]  O. Bouché,et al.  [Targeted biotherapies in digestive oncology: management of adverse effects]. , 2009, Gastroenterologie clinique et biologique.

[14]  P. Novotny,et al.  Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes , 2008, Cancer.

[15]  M. Gipps,et al.  Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. , 2008, Clinical lung cancer.

[16]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[17]  A. Halpern,et al.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Muro,et al.  Clinical management of EGFRI dermatologic toxicities: the European perspective. , 2007 .

[19]  M. Lacouture,et al.  Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. , 2007, Oncology.

[20]  Edward S. Kim,et al.  Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. , 2007, The oncologist.

[21]  E. Van Cutsem,et al.  Clinical management of EGFRI dermatologic toxicities: the European perspective. , 2007, Oncology.

[22]  E. Roé,et al.  Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. , 2006, Journal of the American Academy of Dermatology.

[23]  E. Van Cutsem.  Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. , 2006, The oncologist.

[24]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[27]  B. Gusterson,et al.  Increased EGF receptors on human squamous carcinoma cell lines. , 1986, British Journal of Cancer.